Glycopeptides to drive an anti-tumour immune response and improve outcomes in cancer immunotherapies

Research unit

INNOSUISSE

Project number

101.651 IP-LS

Project title

Glycopeptides to drive an anti-tumour immune response and improve outcomes in cancer immunotherapies (Innolink: 101.651 IP-LS)

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Pharmaceuticals
Abstract (English)	Most cancer patients do not respond to immunotherapies. Altered glycosylation of tumors is a signature of cancer development, making glycans an emerging target. The project studies glycopeptides as novel therapeutics that steer immune responses to control tumor growth and enhance treatment response.